Excellent efficacy of Chong Kun Dang’s ‘Duvie’ published in international journal

Chong Kun Dang(CEO Young-Joo Kim) announced on the 12^th that a study result which structurally revealed strong antidiabetic efficacy and little incidence of adverse drug reactions with a new diabetes therapy ‘Duvie(generic name: lobeglitazone)’ was in Scientific Reports, a U.K. scientific journal.

The study was jointly conducted by Chong Kun Dnag, Professor Byung-Woo Han Seoul National Univers...